BiomedicineNews.net

Biomedicine Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Pneumobase.it

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition


Alopecia areata is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in alopecia areata are not defined limiting clinical development of rational targeted therapies.

Genome-wide association studies ( GWAS ) implicated ligands for the NKG2D receptor ( product of the KLRK1 gene ) in disease pathogenesis.

Researchers at Columbia University ( New York; USA ) have shown that cytotoxic CD8+NKG2D+ T cells are both necessary and sufficient for the induction of alopecia areata in mouse models of disease.

Global transcriptional profiling of mouse and human alopecia areata skin revealed gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-gamma ( IFN-gamma ) response and upregulation of several gamma-chain cytokines known to promote the activation and survival of IFN-gamma–producing CD8+NKG2D+ effector T cells.

Therapeutically, antibody-mediated blockade of IFN-gamma, interleukin-2 ( IL-2 ) or interleukin-15 receptor beta ( IL-15Rbeta ) prevented disease development, reducing the accumulation of CD8+NKG2D+ T cells in the skin and the dermal IFN response in a mouse model of alopecia areata.

Systemically administered pharmacological inhibitors of Janus kinase ( JAK ) family protein tyrosine kinases, downstream effectors of the IFN-gamma and gamma-chain cytokine receptors, eliminated the Interferon signature and prevented the development of alopecia areata, while topical administration promoted hair regrowth and reversed established disease.

Notably, three patients treated with oral Ruxolitinib ( Jakafi; in Europe: Jakavi ), an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human alopecia areata. ( Xagena )

Xing L et al, Nature Medicine 2014 doi:10.1038/nm.3645

XagenaMedicine_2014



Indietro